Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-019457
Filing Date
2025-02-13
Accepted
2025-02-13 10:24:36
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 6135
2 EX-99.A ck0001669811-ex99_a.pdf EX-99.A 87559
3 EX-99.B ck0001669811-ex99_b.pdf EX-99.B 86628
  Complete submission text file 0000950170-25-019457.txt   248102
Mailing Address 1-5-5, OTEMACHI CHIYODA-KU, TOKYO M0 100-8176
Business Address 1-5-5, OTEMACHI CHIYODA-KU, TOKYO M0 100-8176 81-3-5224-1111
MIZUHO FINANCIAL GROUP INC (Filed by) CIK: 0001335730 (see all company filings)

EIN.: 000000000
Type: SCHEDULE 13G
SIC: 6021 National Commercial Banks
(CF Office: 02 Finance)

Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Subject) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94231 | Film No.: 25617901
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)